|
POU5F1P4
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, garcinol anticancer effect significantly attenuated the GBM stem cell-like phenotypes, as reflected by diminished ability of U87MG or GBM8401 to form colonies and tumorspheres and suppressed expression of OCT4 and SOX2.
|
31783691 |
2019 |
|
POU5F1P4
|
0.100 |
Biomarker
|
disease |
BEFREE |
These eGFP-positive-GCs exhibited GSC features and primarily localized to the perivascular region in tumor xenografts, similar to the existence of OCT4-expressing GCs in the perivascular region of human glioblastoma specimens.
|
28216164 |
2018 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of FAT1, EMT (Snail/LOX/Vimentin/N-cad), stemness (SOX2/OCT4/Nestin/REST) and hypoxia markers (HIF-1α/VEGF/PGK1/CA9) was upregulated in ≥39% of GBM tumors (n = 31) with significant positive correlation (p ≤ 0.05) of the expression of FAT1 with LOX/Vimentin/SOX2/HIF-1α/PGK1/VEGF/CA9.
|
28994107 |
2018 |
|
POU5F1P4
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Gene expression profiles of three glioma stem cell line samples, three normal astrocyte samples, three astrocyte overexpressing 4 iPSC-inducing and oncogenic factors (myc(T58A), OCT-4, p53DD, and H-Ras(G12V)) samples, three astrocyte overexpressing 7 iPSC-inducing and oncogenic factors (OCT4, H-Ras(G12V), myc(T58A), p53DD, cyclin D1, CDK4(RC24) and hTERT) samples and three glioblastoma cell line samples were downloaded from the ArrayExpress database (accession: E-MTAB-4771).
|
28952134 |
2017 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GBM U87 cells were cultured with CM and sphere formation, expression of genes related to resistance and CSCs-MGMT, OCT4, SOX2, NOTCH1, MSI1-and protein expression of OCT4 and Nanog were analyzed.
|
27210718 |
2016 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Among astrocytomas, mRNA expression of OCT4, MYC and (less robust) KLF4 increased with malignancy, while in recurrent glioblastomas MYC expression slightly decreased.
|
27600094 |
2016 |
|
POU5F1P4
|
0.100 |
Biomarker
|
disease |
BEFREE |
The involvement of Oct-3/4 in drug resistance of glioblastoma cells was assessed by lactate dehydrogenase assay, efflux assay of an anticancer drug, poly ADP-ribose polymerase cleavage, and in vivo xenograft experiments.
|
25644290 |
2015 |
|
POU5F1P4
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that Oct-3/4-expressing glioblastoma cells have the ability to adapt to low-oxygen environments within tumor masses by promoting tumor angiogenesis through AKT-HIF1 pathway.
|
25348671 |
2015 |
|
POU5F1P4
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, the receptor CXCR6 is restricted in glioblastomas to a small subset of proliferating cells positive for the stem-cell markers Musashi, Nanog, Sox2 and Oct4.
|
23628207 |
2013 |
|
POU5F1P4
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vinculin accumulated along the leading edges of Oct-3/4 expressing-glioblastoma cells and associated with membrane ruffles during cell migration.
|
21938739 |
2012 |
|
POU5F1P4
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated that miR145 negatively regulates GBM tumorigenesis by targeting Oct4 and Sox2 in GBM-CD133(+).
|
22098779 |
2012 |
|
POU5F1P4
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results provide a valuable dataset for understanding gene regulation mechanisms underlying the function of OCT4 in glioblastoma cancer.
|
21960344 |
2011 |